SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

DENVER, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it has assumed all responsibility for direct sales, marketing and distribution of QUELIMMUNE^™ to hospital customers. QUELIMMUNE is SeaStar Medical’s therapeutic device approved for the treatment of pediatric acute kidney injury (AKI) due to sepsis or a septic-like condition.

Read more at globenewswire.com